Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 111.2 kDa. The protein migrates as 140-160 kDa under reducing (R) condition, and 280-320 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human VEGF R3, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) is more than 85% and the molecular weight of this protein is around 260-320 kDa verified by SEC-MALS.
Immobilized Human VEGF-C Protein, His Tag (Cat. No. VEC-H52H3) at 5 μg/mL (100 μL/well) can bind Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) with a linear range of 0.2-8 ng/mL (QC tested).
Immobilized Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) at 5μg/mL (100 μL/well) can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with a linear range of 0.08-0.6 μg/mL (Routinely tested).
Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 19.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Human VEGF-C Protein, His Tag (Cat. No. VEC-H52H3) capture on NTA-Series S sensor chip can bind Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) with an affinity constant of 0.130 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Thyroid Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Medullary thyroid cancer (MTC); Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma | Details |
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Axitinib | PF-01367866; AG-13736; AG-013736 | Approved | Pfizer Inc | 英立达, Inlyta | United States | Carcinoma, Renal Cell | Pf Prism Cv | 2012-01-27 | Lung Neoplasms; Carcinoma, Ductal; Uveal melanoma; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Hepatic Insufficiency; Thyroid Neoplasms; Prostatic Neoplasms, Castration-Resistant; Leukemia, Myeloid, Acute; Lymphoma; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Paraganglioma; Nasopharyngeal Neoplasms; Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoid Tumor; Pheochromocytoma; Carcinoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Kidney Neoplasms; Adrenal Cortex Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Pancreatic Neoplasms; Mesothelioma; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors | Details |
Tivozanib | Kil-8951; AV-951; KRN-951; ASP-4130; KHK-4951; KHK4951; UNII-172030934T | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda, FOTIVDA | EU | Carcinoma, Renal Cell | Recordati Netherlands BV | 2017-08-24 | Wet Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Metastatic breast cancer; Hepatic Insufficiency; Peritoneal Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Biliary Tract Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Solid tumours | Details |
Selpercatinib | ARRY-192; Ret-IN-1; LOXO-292; LY-3527723 | Approved | Array Biopharma | Retevmo, Retsevmo | United States | Medullary thyroid cancer (MTC); Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms | Loxo Oncology Inc | 2020-05-08 | Medullary thyroid cancer (MTC); Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Hepatic Insufficiency; Neuroblastoma; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing; Osteosarcoma; Fibrosarcoma; Sarcoma; Myofibromatosis; Wilms Tumor; Neoplasms; Thyroid Carcinoma, Anaplastic; Colonic Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Renal Insufficiency; Medulloblastoma; Ependymoma; Rhabdomyosarcoma; Hematologic Neoplasms; Solid tumours | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Kidney Neoplasms; Skin Melanoma; Teratoma; Liver Neoplasms; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Lymphoma, B-Cell; HIV Infections; Fibrosarcoma; Intestinal Neoplasms; Fibromatosis, Aggressive; Leukemia; Lymphoma, B-Cell, Marginal Zone; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Abdominal Neoplasms; Pelvic Neoplasms; Polycythemia Vera; Thoracic Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoma; Histiocytoma, Malignant Fibrous; Hemangioblastoma; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Nose Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic neuroendocrine tumors (pNET); Plasmacytoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Carcinoma, Transitional Cell | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Osteosarcoma; Germinoma; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Uterine Cervical Diseases; Genital Neoplasms, Female; Gliosarcoma; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Lung Neoplasms; Nasopharyngeal Carcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Psoriasis; Gastrinoma; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Neoplasm Metastasis; Breast Neoplasms, Male; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Paraganglioma; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Sarcoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Choriocarcinoma; Uterine Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Glioma; Carcinoma, Embryonal; Skin Melanoma; Neoplasms; Herpes Genitalis; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Insulinoma; Pheochromo | Details |
Chloropyramine Hydrochloride | C9; C10; C9A; Y15; CFAK-C4; CFAK-C9; CFAK-C10; CFAK-Y15; CFAK-C9a | Approved | Synopen, Supralgon, Suprastin | Rhinitis, Allergic; Conjunctivitis, Allergic; Asthma | Details | |||||
Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
Fruquintinib | HMPL-013; TAK-113 | Approved | Hutchison Medipharma Ltd | FRUZAQLA, Aiyoute, 爱优特, Elunate | Mainland China | Colorectal Neoplasms | Hutchison Medipharma Ltd | 2018-09-04 | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Metastatic breast cancer; Endometrial Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Neoplasms; Solid tumours; Colonic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Renal Insufficiency; Biliary Tract Neoplasms | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Rhabdomyosarcoma; Solid tumours; Ovarian Neoplasms; Fibromatosis, Aggressive; Kidney Neoplasms; Leukemia, Myeloid; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Islet Cell; Insulinoma; Vipoma; Hemangiosarcoma; Esophageal Neoplasms; Wilms Tumor; Hypertension, Portal; Thyroid Carcinoma, Anaplastic; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Lymphomatoid Granulomatosis; Carcinoma, Transitional Cell; Colonic Neoplasms; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Endocrine Neoplasia Type 2a; Lymphoma, Large-Cell, Immunoblastic; Leukemia-Lymphoma, Adult T-Cell; Carcinoma, | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 3 Clinical | Astrazeneca Plc | Solid tumours; Ovarian Neoplasms; Leiomyosarcoma; Leukemia; Liver Neoplasms; Optic Nerve Glioma; Skin Melanoma; Head and Neck Neoplasms; Biliary Tract Neoplasms; Medulloblastoma; Lymphoma, B-Cell, Marginal Zone; Ependymoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Carcinoma, Renal Cell; Carcinoma; Spinal Cord Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Leukemia, Hairy Cell; Rhabdoid Tumor; Squamous Cell Carcinoma of Head and Neck; Cystadenoma, Serous; Cystadenocarcinoma, Serous; Cystadenocarcinoma, Mucinous; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia-Lymphoma, Adult T-Cell; Hormone-Resistant Prostate Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Carcinoma, Verrucous; Nasopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hypopharyngeal Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Lymphoma, Large-Cell, Immunoblastic; Salivary Gland Neoplasms; Lymphomatoid Granulomatosi | Details |
Sitravatinib | MGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms | Details |
Axitinib intravitreal implant (Ocular Therapeutix) | OTX-TKI | Phase 3 Clinical | Ocular Therapeutix Inc | Wet Macular Degeneration; Macular Degeneration; Diabetic Retinopathy | Details |
AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
Axitinib Implant(Aerie) | AR-14034 SR; AR-14034 | Phase 2 Clinical | Aerie Pharmaceuticals Inc | Macular Degeneration | Details |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
KHK-4951 | Phase 2 Clinical | Kyowa Kirin | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details | |
Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
Amorphous Formulation of Sorafenib in Mesoporous Magnesium Carbonate | DPH001; DPH-001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
EVT-801 | EVT-801 | Phase 1 Clinical | Sanofi Sa (Sanofi Ag) | Solid tumours | Details |
Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
This web search service is supported by Google Inc.